| Genentech USA |
50242024501 |
PHESGO SC - 1200mg/600mg (15mL) Inject Solution |
2020-07-07 |
12707.0000 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.
We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines getting to people who need them. |
None |
38600 |
None |
None |
None |
None |
None |
None |
It is estimated that there are approximately 38,600 patients in the US diagnosed with HER2+ breast cancer. Physicians treating patients with this condition make the determinations on therapeutic options.
PHESGO SC - 1200mg/600mg (15mL) Inject Solution was developed by Genentech USA Inc and was not acquired from a third party. |
None |
| Genentech USA |
50242026001 |
PHESGO SC - 600mg/600mg (10mL) Inject Solution |
2020-07-07 |
8471.0000 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.
We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines getting to people who need them. |
None |
38600 |
None |
None |
None |
None |
None |
None |
It is estimated that there are approximately 38,600 patients in the US diagnosed with HER2+ breast cancer. Physicians treating patients with this condition make the determinations on therapeutic options.
PHESGO SC - 600mg/600mg (10mL) Inject Solution was developed by Genentech USA Inc and was not acquired from a third party. |
None |
| Genentech USA |
50242017507 |
Evrysdi 60mg/80mL oral powder (constituted to 0.75 mg/mL) |
2020-08-17 |
11170.4300 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.
We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines getting to people who need them. |
None |
7200 |
1 |
1 |
None |
None |
None |
None |
Evrysdi 60mg/80mL oral powder (constituted to 0.75 mg/mL) was developed by Genentech USA Inc. and was not acquired from a third party. |
None |
| Genentech USA |
50242000701 |
Enspryng – 120mg/mL Prefilled Syringe |
2020-08-24 |
14615.3900 |
Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.
We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines getting to people who need them. |
None |
25400 |
1 |
1 |
None |
None |
None |
None |
Enspryng – 120mg/mL Prefilled Syringe was developed by Genentech USA Inc and was not acquired from a third party. |
None |
| Gilead Sciences, Inc. |
61958180501 |
HARVONI® (ledipasvir 33.75mg/sofosbuvir 150mg) oral pellets, 28 packets |
2020-05-26 |
31500.0000 |
None |
1 |
None |
None |
1 |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within New Drug Reports. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available.
HARVONI oral pellets were granted orphan drug status by the FDA since it is estimated that, for the product, less than 200,000 patients in the U.S. are affected by a condition that it may be used to treat. However, Gilead is not aware of publicly available information related to the estimated number of patients that may be treated with HARVONI oral pellets. Consistent with Section 127681(c) of the California Health and Safety Code, Gilead is unable to provide an estimated number of patients in its report.
Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead developed this drug product. |
None |
| Gilead Sciences, Inc. |
61958180401 |
HARVONI® (ledipasvir 45mg/sofosbuvir 200mg) oral pellets, 28 packets |
2020-05-26 |
31500.0000 |
None |
1 |
None |
None |
1 |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within New Drug Reports. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available.
HARVONI oral pellets were granted orphan drug status by the FDA since it is estimated that, for the product, less than 200,000 patients in the U.S. are affected by a condition that it may be used to treat. However, Gilead is not aware of publicly available information related to the estimated number of patients that may be treated with HARVONI oral pellets. Consistent with Section 127681(c) of the California Health and Safety Code, Gilead is unable to provide an estimated number of patients in its report.
Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead developed this drug product. |
None |
| Gilead Sciences, Inc. |
61958150401 |
SOVALDI® (sofosbuvir 150mg) oral pellets, 28 packets |
2020-05-26 |
28000.0000 |
None |
1 |
None |
None |
1 |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within New Drug Reports. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available.
SOVALDI oral pellets were granted orphan drug status by the FDA since it is estimated that, for the product, less than 200,000 patients in the U.S. are affected by a condition that it may be used to treat. However, Gilead is not aware of publicly available information related to the estimated number of patients that may be treated with SOVALDI oral pellets. Consistent with Section 127681(c) of the California Health and Safety Code, Gilead is unable to provide an estimated number of patients in its report.
Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead developed this drug product. |
None |
| Gilead Sciences, Inc. |
61958150501 |
SOVALDI® (sofosbuvir 200mg) oral pellets, 28 packets |
2020-05-26 |
28000.0000 |
None |
1 |
None |
None |
1 |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within New Drug Reports. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available.
SOVALDI oral pellets were granted orphan drug status by the FDA since it is estimated that, for the product, less than 200,000 patients in the U.S. are affected by a condition that it may be used to treat. However, Gilead is not aware of publicly available information related to the estimated number of patients that may be treated with SOVALDI oral pellets. Consistent with Section 127681(c) of the California Health and Safety Code, Gilead is unable to provide an estimated number of patients in its report.
Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead developed this drug product. |
None |
| GlaxoSmithKline |
00173089601 |
BLENREP INJ 100 MG |
2020-08-21 |
8277.0000 |
None |
1 |
3500 |
1 |
1 |
None |
None |
None |
None |
Multiple myeloma is the second most common blood cancer in the US and is generally considered treatable, but not curable. In the US, more than 32,000 people are estimated to be diagnosed with multiple myeloma this year and nearly 13,000 people will die from the disease. Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments. GSK estimates that there are roughly 3,500 patients within the U.S. at a given time who suffer from multiple myeloma and would be potential candidates to use the product according to the current label. Diagnosed patients may or may not be prescribed BLENREP (NDC: 00173089601) depending on their known resistance to the medicines and other patient specific factors such as allergic reactions or other medical conditions that may preclude a patient's ability to be effectively treated with BLENREP (NDC: 00173089601).
GSK has not released BLENREP's (NDC: 00173089601) marketing or pricing plan information in the public domain and is limiting its response to that which is publicly available pursuant to California Code of Regulations, Title 22, Division 7, Chapter 9.5 Section 96076(c). |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462049430 |
Deferasirox Tablets for Oral Suspension, 125 mg |
2020-01-17 |
675.8900 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA data for the 12 months ending November 2019 is 11,313 prescriptions for Deferasirox Tablets for Oral Suspension. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462049530 |
Deferasirox Tablets for Oral Suspension, 250 mg |
2020-01-17 |
1351.7600 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA data for the 12 months ending November 2019 is 11,313 prescriptions for Deferasirox Tablets for Oral Suspension. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462049630 |
Deferasirox Tablets for Oral Suspension, 500 mg |
2020-01-17 |
2703.4600 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA data for the 12 months ending November 2019 is 11,313 prescriptions for Deferasirox Tablets for Oral Suspension. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462072401 |
Chlorzoxazone Tablets USP, 375 mg |
2020-05-27 |
744.2900 |
None |
1 |
6570 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, IQVIA MAT data for the 12 months ending April 2020 is 6,570 prescriptions for 375 mg , and 27,635 prescriptions for 750 mg. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462072501 |
Chlorzoxazone Tablets USP, 750 mg |
2020-05-27 |
832.2500 |
None |
1 |
27635 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, IQVIA MAT data for the 12 months ending April 2020 is 6,570 prescriptions for 375 mg , and 27,635 prescriptions for 750 mg. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462042169 |
Atovaquone Oral Suspension USP,750 mg'5ml 42X5 |
2020-07-31 |
1239.0000 |
None |
1 |
120846 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, however IQVIA MAT data for the 12 months ending June 2020 is 120,846 prescriptions for the total market. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462068201 |
Sirolimus Tablets, .5 mg |
2020-10-23 |
694.3800 |
None |
1 |
213589 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, IQVIA MAT data for the 12 months ending September 2020 is 213,589 prescriptions. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Glenmark Pharmaceuticals Inc., USA |
68462068301 |
Sirolimus Tablets, 1 mg |
2020-10-23 |
1388.7700 |
None |
1 |
213589 |
None |
None |
None |
None |
None |
None |
Marketing/Pricing Plan not in the public domain or publically available. Estimated patients not known. However, IQVIA MAT data for the 12 months ending September 2020 is 213,589 prescriptions. Acquisition fields left blank as drug was developed by Glenmark. |
None |
| Granules Pharmaceuticals Inc. |
70010005401 |
Butalbital and Acetaminophen Capsules, 50 mg/300 mg, 100 Count |
2020-02-19 |
1028.3300 |
None |
1 |
0 |
None |
None |
None |
None |
None |
None |
The dates mentioned here are accurate and the dates appear on NDC lookup and Medspan are tentative marketing dates given during Initial ANDA SPL submission. |
None |
| Granules Pharmaceuticals Inc. |
70010004401 |
Butalbital, Acetaminophen and Caffeine Capsules, 50 mg/300 mg/40 mg, 100 Count |
2020-05-05 |
88.4200 |
None |
1 |
100 |
None |
None |
None |
None |
None |
None |
The dates mentioned here are accurate and the dates appear on NDC lookup and Medspan are tentative marketing dates given during Initial ANDA SPL submission. |
None |
| Granules Pharmaceuticals Inc. |
70010000201 |
COLCHICINE 0.6MG Tablets, 100count |
2020-05-13 |
107.5500 |
None |
1 |
100 |
None |
None |
None |
None |
None |
None |
The dates mentioned here are accurate and the dates appear on NDC lookup and Medspan are tentative marketing dates given during Initial ANDA SPL submission. |
None |
| Granules Pharmaceuticals Inc. |
70010000203 |
COLCHICINE 0.6MG Tablets, 30count |
2020-05-13 |
39.2700 |
None |
1 |
100 |
None |
None |
None |
None |
None |
None |
The dates mentioned here are accurate and the dates appear on NDC lookup and Medspan are tentative marketing dates given during Initial ANDA SPL submission. |
None |